InternationalUSRemember you can easily switch between MIP US and MIP International at any time

MIP European Life Sciences Forum 2017 - Agenda

June 29, Le Méridien Piccadilly, London




Agenda





Delegates

Photos

Venue

Contact us

Download the brochure here



08:30 Registration

09:00 Opening remarks by James Nurton, managing editor, Managing IP

09:10 Practical planning for Brexit - key risk areas for life sciences companies

  • Parallel imports for pharma products and freedom to operate considerations
  • Trade mark protection – what will happen to existing marks & the future of non-traditional trade marks
  • Cross border injunctions
  • Customs seizures and battling counterfeits

Jeremy Blum, partner, Bristows


10:00 Second medical use patents - can a consensus be reached?

  • Solving practical problems: Warner Lambert v Actavis
  • Practically obtaining and enforcing second medical use patents (validity issues)
  • Examining evolving case law in different jurisdictions
  • Reviewing the issue of 'skinny labelling' with generics

Marianne Schaffner, partner, Dechert
David Cottam, senior director, associate general patent counsel, Teva Europe


10:50 Coffee break and networking



11:20 Supplementary protection certificates: striking the balance to protecting rights

  • Essential updates from key SPCs cases over the past year
  • Combination products judgements
  • Brexit and what this means for SPCs
  • Looking to the future: what should be changed in SPC regulation?

Paul Chapman, head of legal practice, Avidity IP
Jürgen Dressel, head of global patent litigation strategy, Novartis Pharma


12:10 Challenges and regulatory issues with digital health

  • Medical devices and sophisticated diagnostics
  • Government initiatives and legislation to help
  • What trends are we seeing in the landscape to block the launch of new diagnostics?
  • Exploring the role of IoT in digital health solutions: product liability and IP issues

Niklas Mattsson, partner, Awapatent
Anneliese Hassenbuerger
, senior patent attorney, Novartis


13:00 Lunch and networking


13:50 Coordinating UK, EU and US patent strategies: updates from the US

  • The 101 issue: Patent Eligibility in the US - what are the implications for EU patent holders?
  • Inter-partes reviews: challenges and procedural tactics to make your company IPR ready
  • Drawing comparisons between IPRs and revocation actions in Europe

Jennifer Roscetti, partner, Finnegan Henderson Farabow Garrett & Dunner
Erin Sommers, partner, Finnegan Henderson Farabow Garrett & Dunner


 14:40 Unified Patent Court - final preparations for the sunrise period

  • To what extent will the UPC be pro-patentee?
  • Taking steps towards 'troll proofing' your business
  • Alignment of UK courts and other national patent courts within the EU
  • Future forecast: will the UK remain in the system post-Brexit?

Penny Gilbert, partner, Powell Gilbert (moderator)
Francis Tierney, senior patent director, AstraZeneca
Sean Alexander, senior director, European patent counsel, Eli Lilly & Company
Peter Thomsen
, global head IP policy & senior manager IP litigation, Novartis


15:30 Coffee break and networking


15:50 Strategic considerations for dealing with patent portfolios covering biologics

  • Examining the approach of national courts
  • Using declaratory relief to deal with divisional applications
  • Related legal issues that affect the rate of entr y of biosimilars
  • Can UK courts be pragmatic and give commercial solutions? Fujifilm Kyowa Biologics v AbbVie

Luke Kempton, partner, Gowling WLG
Dean Thomas, director IP, Glenmark Pharmaceuticals


16:40 Effective litigation management strategies

  • Annual review and trends of key jurisdictions
  • Coordinating litigation across Europe in life sciences: is there a shift towards harmonisation?
  • Interplay between regulatory regimes and patent litigation

Johan Renes, partner, DLA Piper
Paul Reeskamp
, partner, DLA Piper

17:30 Close of conference


 



 

Sponsors

Avidity IP

Bristows

Dechert LLP

Finnegan

Gowling WLG

Powell Gilbert








profile

Managing IP

ManagingIP

ManagingIP profile

Well done to all involved! #AIPPI2017 #CII https://t.co/q5PbWThHjf

Oct 17 2017 12:59 ·  reply ·  retweet ·  favourite
ManagingIP profile

Friends in high places? #AIPPI2017 https://t.co/YnqhCgqIrh

Oct 17 2017 12:58 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @andreabrewster3: This event is for all IP professionals, of all genders @TheCIPA @CITMAuk @ipfederation @ip_out @ManagingIP See you the…

Oct 17 2017 12:54 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null null null

October 2017

Courts grapple with scope of patent protection

The Supreme Court’s decision in Actavis v Eli Lilly introduced a doctrine of equivalents and arguably also established a doctrine of prosecution history estoppel in the UK. We look at the law across Europe, and the impact the decision might have. Kingsley Egbuonu, Michael Loney and James Nurton set the scene



Most read articles

Supplements